Mitral regurgitation (MR) is one of the most prevalent valve disorders and has numerous etiologies, including primary (organic) MR, due to underlying degenerative/structural mitral valve (MV) pathology, and secondary (functional) MR, which is principally caused by global or regional left ventricular remodeling and/or severe left atrial dilation. Diagnosis and optimal management of MR requires integration of valve disease and heart failure specialists, MV cardiac surgeons, interventional cardiologists with expertise in structural heart disease, and imaging experts. The introduction of transcatheter MV therapies has highlighted the need for a consensus approach to pragmatic clinical trial design and uniform endpoint definitions to evaluate outcomes in patients with MR. The Mitral Valve Academic Research Consortium is a collaboration between leading academic research organizations and physician-scientists specializing in MV disease from the United States and Europe. Three in-person meetings were held in Virginia and New York during which 44 heart failure, valve, and imaging experts, MV surgeons and interventional cardiologists, clinical trial specialists and statisticians, and representatives from the U.S. Food and Drug Administration considered all aspects of MV pathophysiology, prognosis, and therapies, culminating in a 2-part document describing consensus recommendations for clinical trial design (Part 1) and endpoint definitions (Part 2) to guide evaluation of transcatheter and surgical therapies for MR. The adoption of these recommendations will afford robustness and consistency in the comparative effectiveness evaluation of new devices and approaches to treat MR. These principles may be useful for regulatory assessment of new transcatheter MV devices, as well as for monitoring local and regional outcomes to guide quality improvement initiatives. (J Am Coll Cardiol 2015;66:308-21)
evaluation and to guide clinical care decision-making (1) . Equally important is the assessment of clinically relevant endpoints reflecting the safety and efficacy of MR therapies and the use of consensus definitions to ensure that such endpoints are meaningful and consistent across studies (2) . In addition to randomized trials, the use of consistent definitions is important for observational and administrative databases that lack a concurrent control. Academic Research Consortium (ARC) consensus endpoints have been introduced for drug-eluting stents (3), for transcatheter aortic valve replacement (TAVR) (4, 5) , and for bleeding complications (6) , and have been adopted to improve the cross-evaluation of studies (7) .
As discussed in part 1 of this document, MVARC recommends that all primary and major secondary endpoint events within the clinical trial framework are adjudicated utilizing pre-specified definitions by an independent committee using original source documents (1) . Given the varied nature of these events, depending on the specific study, the adjudication committee should ideally include a heart failure specialist, a cardiologist specializing in MV disease, an interventional cardiologist skilled in structural heart disease interventions (ideally MV procedures), an experienced MV cardiac surgeon, an imaging specialist, and a stroke neurologist. For tracking outcomes of MV interventions in nonrandomized clinical studies or in administrative databases, for cost or logistical reasons it may not be possible to employ an independent central adjudication committee. In such cases, the use of uniform definitions will at least ensure consistency over time and across studies. 
HOSPITALIZATION (OR REHOSPITALIZATION)
Hospitalization is a clinically meaningful measure of morbidity, with substantial clinical and economic implications (8, 9) . The preferred definition of hospitalization (or rehospitalization) after discharge from an MV procedure appears in Table 3 . The causes of hospitalization can be further subclassified as in Table 3 .
In particular, hospitalization due to new or worsening heart failure is an important metric after MV interventions that may serve as a primary endpoint in MV device trials. It is acknowledged, however, that hospitalization rates vary across different countries, regions, and hospital systems, in part due to variations in local practice patterns. The proposed definitions attempt to account for some of these variances.
HEART FAILURE HOSPITALIZATION. The mortality rate for patients hospitalized for worsening heart failure is w4% to 7% during the in-hospital phase, w11% to 15% at 1 month, and w33% at 1 year (10-13).
The 30-day and 1-year rates of repeat all-cause hospitalization for patients discharged for heart failure are approximately 25% and 70%, respectively (14, 15) .
One-half of these readmissions are due to recurrent heart failure. As a clinical trial endpoint, heart failure hospitalization must be carefully defined and adjudicated by a clinical events committee using specific, objective criteria.
The definition for heart failure hospitalization requires: 1) a hospital stay for worsening heart failure for $24 h; and 2) administration of intravenous or mechanical heart failure therapies ( Table 3 ). An emergency room stay for $24 h would qualify as a heart failure hospitalization endpoint, even absent formal hospital admission, as such a prolonged stay represents a severe episode of heart failure. The diagnosis of worsening heart failure is on the basis of: 1) symptoms of worsening heart failure such as increased dyspnea, and some element of heart failure, or major heart failure exacerbation with secondary bronchospasm).
Only primary heart failure should be considered a valid criterion for heart failure hospitalization, although secondary heart failure hospitalizations should also be reported and used for sensitivity analysis.
Finally, some trials have used a broader definition of worsening heart failure events to capture not only heart failure hospitalizations but also heart failure hospitalization "equivalents" (16) . This approach includes a definition of heart failure hospitalization similar to the MVARC definition, plus heart failurerelated emergency department visits and urgent (unscheduled) clinic visits requiring treatment with intravenous heart failure therapies or substantial augmentation of oral heart failure medications. These latter outpatient visits are "softer" events, are often less well documented and more difficult to adjudicate, and comprise only about 10% of all worsening heart failure events (17) . As such, the MVARC recommends that they not be included in the principal endpoint definition of heart failure hospitalization.
Collecting and adjudicating such events may be useful, however, for secondary sensitivity analyses and for cost/comparative effectiveness assessments. If analysis of these outpatient events is needed to comprehensively characterize device performance over time, pre-specified definitions sufficient to allow accurate data capture regarding their occurrence are required. In the future, as comprehensive outpatient management of advanced heart failure becomes more frequent, and as improvements in electronic health record infrastructure support more robust documentation, elements of outpatient heart failure control might provide more informative data supporting clinical insight into devices used for MR. Hospitalization is defined as admission to an inpatient unit or ward in the hospital for $24 h, including an emergency department stay. Hospitalizations planned for pre-existing conditions are excluded unless there is worsening of the baseline condition.
Hospitalization Is Further Subclassified as:
I. Heart failure hospitalization: Both of the following additional criteria are present: i. Symptoms, signs and/or laboratory evidence of worsening heart failure (see text, section Heart Failure Hospitalization) ii. Administration of intravenous or mechanical heart failure therapies (see text, section Heart Failure Hospitalization) Patients hospitalized with heart failure are further subclassified as:
IA. Primary (cardiac related) heart failure hospitalization IB. Secondary (noncardiac related) heart failure hospitalization II. Other cardiovascular hospitalization: such as for coronary artery disease, acute myocardial infarction, hypertension, cardiac arrhythmias, cardiomegaly, pericardial effusion, atherosclerosis, stroke, or peripheral vascular disease without qualifying heart failure III. Noncardiovascular hospitalization: not due to heart failure or other cardiovascular causes, as defined above
NEUROLOGICAL EVENTS
Stroke is a critical endpoint in cardiovascular clinical trials, often considered second only to mortality in importance to patients and physicians. However, Although atrial septal defects after trans-atrial procedures are not usually of hemodynamic significance and do not require repair, the criteria for a significant residual atrial septal defect should be pre-specified. Table 9) . Pacemaker or Overt bleeding either associated with a drop in the hemoglobin of $3.0 g/dl ‡ or requiring transfusion of $3 U of whole blood or packed RBCs AND does not meet criteria of life-threatening or extensive bleeding.
III. Extensive
Overt source of bleeding with drop in hemoglobin of $4 g/dl ‡ or whole blood or packed RBC transfusion $4 U within any 24-h period, or bleeding with drop in hemoglobin of $6 g/dl ‡ or whole blood or packed RBC transfusion $4 U (BARC type 3b) within 30 days of the procedure. IV. Life-threatening Bleeding in a critical organ, such as intracranial, intraspinal, intraocular, or pericardial necessitating surgery or intervention, or intramuscular with compartment syndrome OR bleeding causing hypovolemic shock or hypotension (systolic blood pressure <90 mm Hg lasting >30 min and not responding to volume resuscitation) or requiring significant doses of vasopressors or surgery. V. Fatal
Bleeding adjudicated as being a proximate cause of death. Severe bleeding adjudicated as being a major contributing cause of a subsequent fatal complication, such as MI or cardiac arrest, is also considered fatal bleeding. Bleeding that is not actionable and does not cause the patient to seek unscheduled performance of studies, hospitalization, or treatment by a health care professional. May include episodes leading to self-discontinuation of medical therapy by the patient without consulting a health care professional. Type 2 Any overt, † actionable sign of hemorrhage (e.g., more bleeding than would be expected for a clinical circumstance, including bleeding found by imaging alone) that does not fit the criteria for type 3, 4, or 5 but does meet $1 of the following: requiring nonsurgical medical intervention by a health care professional, leading to hospitalization or increased level of care, or prompting evaluation. Type 3a Overt* bleeding plus hemoglobin drop of 3 to <5 g/dl ‡ (provided drop is related to bleed) Any transfusion with overt bleeding Type 3b
Overt bleeding plus hemoglobin drop $5 g/dl ‡ (provided drop is related to bleed) Cardiac tamponade Bleeding requiring surgical intervention for control (excluding dental/nasal/skin/hemorrhoid) Bleeding requiring IV vasoactive agents Type 3c
Intracranial hemorrhage (does not include microbleeds or hemorrhagic transformation but does include intraspinal bleeding) Subcategories confirmed by autopsy, imaging, or lumbar puncture Intraocular bleeding compromising vision Type 4 (periprocedural) Perioperative intracranial bleeding #48 h Reoperation after closure of incision site for the purpose of controlling bleeding Transfusion of $5 U whole blood or packed RBCs within 48-h period of the index procedure Chest tube output $2 l within 24-h period Type 5a: Probable fatal bleeding. No autopsy or imaging confirmation but clinically suspicious. Type 5b:
Definite fatal bleeding. Overt bleeding, autopsy, or imaging confirmation.
*Modified with permission from VARC-2 (5). †"Overt" bleeding is defined by any of the following criteria being met: Reoperation after closure of sternotomy for the purpose of controlling bleeding; chest tube output >2 l within any 24-h period, >350 ml within the first post-operative hour, $250 ml within the second post-operative hour, or >150 ml within the third post-operative hour; or visible bleeding from the vascular system either at or remote from the access/surgical site. ‡Adjusted for the number of units of blood transfused (1 U packed red blood cells or whole blood is equivalent to 1 g/dl hemoglobin). §Modified from BARC (6) . Table 10 .
Technical success, measured at the time of the patient's exit from the cardiac catheterization laboratory, reflects the ability of the device to be deployed as intended and the delivery system successfully retrieved without procedural mortality or need for emergency surgery or intervention.
Device success, measured at 30 days and at all follow-up intervals thereafter, characterizes not only the acute "technical" performance of the device and delivery system, but the effectiveness of the device in reducing the severity of MR by a pre-specified amount or to a pre-specified level, as assessed by an independent echocardiographic core laboratory, without device-related complications. By MVARC criteria, "optimal" device success requires a reduction in post-procedural MR to no more than trace levels. "Acceptable" device success is defined as a reduction in post-procedure MR by at least 1 class (i.e., from severe to moderate or less; from moderate to mild or less; or from mild to none). Alternatively, if the 4þ numerical classification is used to grade MR severity, "optimal" device success is defined as a reduction in post-procedural MR to 0þ or trace, and Table 10 . For emerging mitral valve procedures in which the frequency of major arrhythmias and conduction system disturbances is unknown, continuous rhythm monitoring for at least 48 h in the post-procedural period is recommended to maximize the detection of arrhythmias and conduction system disturbances. (e.g., home or assisted living facility), no repeat hospitalizations for the underlying condition (e.g., MR or heart failure), and sustained improvement in symptoms, functional status, and quality-of-life, as detailed in Table 10 .
DEVICE-RELATED ENDPOINTS
In addition to overall device and procedural success, device-related specific endpoints that are important to consider include subcategories of device access and delivery-related success and complications, acute and chronic device function, and device-related complications. The endpoints presented in Table 11 represent a framework for device-related endpoints that should be considered, adjusted as appropriate for each particular device.
CONCLUSIONS
The ARC initiative grew out of the need for prag- I. Technical success (measured at exit from the catheterization laboratory) All of the following must be present: I. Absence of procedural mortality; and II. Successful access, delivery, and retrieval of the device delivery system; and III. Successful deployment and correct positioning of the first intended device; and IV. Freedom from emergency surgery or reintervention related to the device or access procedure.
II. Device success (measured at 30 days and at all later post-procedural intervals)
All of the following must be present: I. Absence of procedural mortality or stroke; and II. Proper placement and positioning of the device; and III. Freedom from unplanned surgical or interventional procedures related to the device or access procedure; and IV. Continued intended safety and performance of the device, including:
a. No evidence of structural or functional failure (see Table 11 , part I) b. No specific device-related technical failure issues and complications (see Table 11 , part II) c. Reduction of MR to either optimal or acceptable levels* without significant mitral stenosis (i.e., post-procedure EROA is $1. All of the following must be present: I. Device success (either optimal or acceptable), and II. Patient returned to the pre-procedural setting: and III. No rehospitalizations or reinterventions for the underlying condition (e.g., mitral regurgitation, heart failure); and IV. Improvement from baseline in symptoms (e.g., NYHA improvement by $1 functional class); and V. Improvement from baseline in functional status (e.g., 6-min walk test improvement by $50 m); and VI. Improvement from baseline in quality-of-life (e.g., Kansas City Cardiomyopathy Questionnaire improvement by $10) *MR reduction is considered optimal when post-procedure MR is reduced to trace or absent. MR reduction is considered acceptable when post-procedure MR is reduced by at least 1 class or grade from baseline and to no more than moderate (2þ) in severity. For clinical trials and registry studies, assessment of baseline and post-procedure MR must be made by an echocardiographic core laboratory. For large observational databases, baseline and post-procedure MR may be assessed by physicians trained in echocardiographic evaluation. †For 30-day evaluation of device success, the results from an immediate post-procedural transesophageal echocardiogram and from a transthoracic echocardiogram taken within 24 to 48 h post-procedure may be used if the 30-day echocardiogram is absent. Device success determinations at post-procedural intervals beyond the initial 30 days should reflect findings from the patient history and an echocardiographic study obtained within the relevant pre-specified follow-up window. Conversion to open mitral valve surgery during a transcatheter procedure, subclassified as -Secondary to mitral valve apparatus damage or dysfunction, requiring surgical valve repair or replacement, or -Secondary to procedural complications (such as cardiac perforation, removal of an embolized device, and so on) Device malpositioning -Ectopic device placement: permanent deployment of a device in a location other than intended -Device migration: after initial correct positioning, the device moves within its initial position but not leading to device embolization -Device embolization: the device moves during or after deployment such that it loses contact with its initial position Device detachment -Partial: detachment of part of the device from the initial position without embolization -Complete: detachment leading to device embolization or ectopic device placement Device fracture -Major: a break, tear, perforation, or other structural defect in the device (stent, housing, leaflet, arm, and so on) resulting in device failure, resulting in recurrent symptoms, or requiring reintervention, or -Minor: a break, tear, perforation, or other structural defect in the device (stent, housing, leaflet, arm, and so on) not resulting in device failure, not resulting in recurrent symptoms, and not requiring reintervention Damage to the native mitral valve apparatus -Chords -Papillary muscles -Leaflets -Mitral annulus Interaction with nonmitral valve intracardiac structures -Left ventricular outflow tract obstruction (gradient increase $10 mm Hg from baseline) -Aortic valve regurgitation ($ moderate or 2þ) -Other Device thrombosis, defined as any thrombus attached to or near an implanted valve, subclassified as: -Major: occludes part of the blood flow path, interferes with valve function (e.g., immobility of 1 or more leaflets), is symptomatic, or is sufficiently large to warrant treatment, or -Minor: incidental finding on echocardiography or other imaging test that is not major Endocarditis -Any 1 of the following: n Fulfillment of the modified Duke endocarditis criteria (61), or n Evidence of abscess, paravalvular leak, pus, or vegetation confirmed as secondary to infection by histological or bacteriological studies during an operation or autopsy.
-Should be further subclassified by organism, and early (<1 yr) vs. late ($1 yr) Hemolysis -The presence of a paravalvular leak on transesophageal or transthoracic echocardiography plus anemia requiring transfusion plus increased haptoglobin and/or LDH levels; should be confirmed by a hematologist Other device-specific endpoints -The number of devices (e.g., clips, neochords) used by intent to achieve the desired reduction in MR -The need for unplanned use of additional devices (e.g., valves, clips, neochords) as a result of failed device delivery, device detachment, device fracture, or other device system failure -If surgery is required, inability to perform mitral valve repair because of the presence of or anatomic changes from the device LDH ¼ lactate dehydrogenase; Qp ¼ pulmonary blood flow; Qs ¼ systemic blood flow; other abbreviations as in 
